Seven FDA advisers have disclosed ties to the peptide industry. They're voting on whether to clear the injections for pharmacy use.

The Food and Drug Administration's Pharmacy Compounding Advisory Committee opens two days of votes Thursday on whether to put seven injectable peptides on a federal list that compounding pharmacies can use. Peptides are short chains of amino acids, the building blocks of proteins, marketed online in vials for muscle gain, recovery, and anti-aging. The FDA's own career scientists say the clinical evidence is too thin to support a wider pharmacy channel, and outside safety experts agree.

"There aren't that many other substances people are injecting into themselves where you see that the clinical evidence is so lacking," Rita Jew, president of the Institute for Safe Medication Practices, said in comments reported by the Associated Press ahead of the meeting.

The votes themselves do not change the law. They produce the institutional signal the FDA then has to ratify, modify, or override. Under Health Secretary Robert F. Kennedy Jr., who has called himself a "big fan" of peptides and has vowed to roll back Biden-era compounding restrictions, the distance between a panel yes and a final agency action has shortened.

The conflict-of-interest count is the unusual part. At least seven of the panel's roughly 20 seated outside advisers have disclosed financial ties to the peptide industry, including wellness clinics, compounding pharmacies, and consulting work. FDA added additional academics without industry ties in the days before the meeting, in a move the agency framed as broadening the panel. The disclosed-tie count remained.

The panel's job, set out in the FDA's Federal Register notice for the meeting, is to weigh the bulk drug substances background document and vote on whether each nominated peptide belongs on the 503A list, the list of substances compounding pharmacies are allowed to mix. A yes vote places the substance in Category 1, cleared for compounding under federal rules. A no keeps it in Category 2, excluded. Orrick's regulatory analysis walks through how the agency landed at this meeting: FDA removed 12 peptides from Category 2 earlier in 2026 and scheduled the PCAC sessions to consider whether each one belongs in Category 1. The RAPS regulatory coverage of the bulk drug substances list lays out the same arc, and the FDA's advisory committee calendar confirms the July 23-24 dates.

Empower Pharmacy, a compounding pharmacy that sells peptides, frames the meeting as a patient-access issue rather than a safety one. That position is shared by the wellness influencers, podcasters, and "MAHA" advocates who have spent the past two years selling the products to consumers online. Their visibility is the reason the wire led with Joe Rogan and Gary Brecka. They are the marketing channel, not the policy mechanism.

The FDA's career staff has been on the record for months. Their position, in the background document and in public comments, is that there is not enough clinical data to support moving any of the nominated peptides into Category 1. The agency can follow that finding, override it, or split the difference and add only a subset. The agency has at times gone against the recommendations of its own advisory panels.

Watch the FDA's response to the vote, not the vote itself. If the agency ratifies a wide Category 1 placement despite its own staff's findings, the panel-conflict count will be the story. If the FDA modifies or rejects the placements, the institutional signal from the votes will have functioned the way advisory committees are supposed to function: producing a record the agency can either follow or set aside in writing, on the record, with reasons. Either way, the disclosed-tie count, the FDA career-scientist record, and the HHS pressure line are now a reusable template for the next advisory committee that touches an industry with a marketing channel.